Over one in four employers is exploring the expansion of covered abortion services, according to a new report from the International Foundation of Employee Benefit Plans. The Post-Dobbs Employer Coverage: July 2022 Pulse Survey revealed current abortion coverage offerings and future considerations. When asked about making changes to current coverage for abortion services, employers responded with the following:

  • No changes to current coverage levels – 46%
  • Don’t know/wait and see – 26%
  • Exploring expansion of covered abortion services – 26%
  • Unable to make plan changes due to appliable legal requirements – 2%

Less than 1% said they are exploring a reduction in or elimination of covered abortion services.

From legal complexities to impact on worker recruitment/retention, many employers are grappling with concerns resulting from the Supreme Court Dobbs decision, including:

  • Legal ramifications – 35%
  • Managing worker expectations – 15%
  • Administrative complexity – 13%
  • Impact on worker recruitment/retention – 7%
  • Additional costs – 6%
  • Potential reputation/public relations issues – 5%
  • Coordinating multiple plans – 2%

Other cited concerns include employee health ramifications, future division amongst workers, mental health impacts, religious-based plans and confusion about whether to provide travel and lodging per IRS guidelines.

Regarding abortion services, employers reported currently covering:

  • Non-elective/medically necessary services – 73%
  • Elective/nonmedically necessary services – 60%
  • Medications – 52%
  • Telehealth – 32%
  • Travel to location where services are performed – 10%
  • Lodging near location where services are performed – 9%

For more information on the Post-Dobbs Employer Coverage: July 2022 Pulse Survey results, visit www.ifebp.org/dobbsimpact

Staff

Recommended Posts

Open pharmacy pill containers on a pile of 20 dollar bills.

What the Executive Order Increasing PBM Fee Transparency Means for Employers

Amanda Wilke, CEBS
 

On April 15, 2025, President Trump signed the executive order (EO) “Lowering Drug Prices by Once Again Putting Americans First,” which includes specific actions to be taken by federal agencies to reduce prescription drug costs, improve transparency and increase competition in the […]

GLP-1 Drug Coverage Continues to Rise in Canada 

Rebecca Plier
 

New Survey Data Reveals Prior Authorization or Other Utilization Management Strategies, Eligibility Requirements, Annual Maximum as Leading Cost Control Methods  A new survey report from the International Foundation of Employee Benefit Plans reveals updated Canadian employer coverage and cost-control mechanisms surrounding glucagon-like […]

GLP-1 Drugs Responsible for Over Ten Percent of Annual Claims 

Rebecca Plier
 

New Survey Data Reveals Rise of GLP-1 Drug Claims, With Utilization Management and Eligibility Requirements as Leading Cost-Control Mechanisms   A new survey report from the International Foundation of Employee Benefit Plans reveals updated U.S. employer coverage and claims representation surrounding glucagon-like peptide-1 […]